Elixinol Wellness Limited (FRA:E8M)
Germany · Delayed Price · Currency is EUR 0.0040
-0.0005 (-11.11%)
At close: Jan 23, 2026
Elixinol Wellness Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 15.85 | 14.96 | 8.27 | 7.06 | 9.34 | 15.01 | |
Revenue Growth (YoY) | 36.79% | 80.87% | 17.21% | -24.45% | -37.79% | -51.13% |
Cost of Revenue | 10.18 | 9.6 | 5 | 4.07 | 7.22 | 8.34 |
Gross Profit | 5.67 | 5.36 | 3.27 | 2.99 | 2.12 | 6.67 |
Selling, General & Admin | 9.76 | 8.78 | 8.58 | 12.28 | 18.82 | 29.07 |
Other Operating Expenses | 0.76 | 0.54 | -0.54 | -0.51 | -0.5 | -0.22 |
Operating Expenses | 11.24 | 10.41 | 9.31 | 12.74 | 20 | 31.77 |
Operating Income | -5.57 | -5.05 | -6.04 | -9.75 | -17.89 | -25.1 |
Interest Expense | -0.43 | -0.21 | -0.1 | -0.07 | -0.09 | -0.05 |
Interest & Investment Income | 0.01 | 0.03 | 0.21 | 0.02 | 0.05 | 0.1 |
Earnings From Equity Investments | - | - | - | - | - | -1.08 |
Currency Exchange Gain (Loss) | 0 | 0.01 | -0.01 | -0.04 | 0.08 | -0.07 |
Other Non Operating Income (Expenses) | - | - | - | - | -0.33 | -4.7 |
EBT Excluding Unusual Items | -5.99 | -5.22 | -5.94 | -9.84 | -18.18 | -30.9 |
Impairment of Goodwill | - | - | - | - | - | -28.71 |
Gain (Loss) on Sale of Investments | -0.09 | -0.09 | -1.33 | - | - | -4.73 |
Gain (Loss) on Sale of Assets | 0 | -0 | -0 | 0.03 | -0.08 | -0.26 |
Asset Writedown | -0.06 | - | -0.24 | -0.77 | -0.75 | -36.04 |
Other Unusual Items | - | - | - | 0.01 | 1.92 | 0.37 |
Pretax Income | -5.65 | -5.31 | -7.5 | -10.57 | -17.09 | -100.28 |
Income Tax Expense | -3.59 | -3.59 | 0 | 0 | -0.07 | 4.2 |
Earnings From Continuing Operations | -2.06 | -1.72 | -7.51 | -10.57 | -17.03 | -104.48 |
Net Income to Company | -2.06 | -1.72 | -7.51 | -10.57 | -17.03 | -104.48 |
Minority Interest in Earnings | - | - | - | - | - | -0.03 |
Net Income | -2.06 | -1.72 | -7.51 | -10.57 | -17.03 | -104.51 |
Net Income to Common | -2.06 | -1.72 | -7.51 | -10.57 | -17.03 | -104.51 |
Shares Outstanding (Basic) | 203 | 155 | 59 | 40 | 39 | 22 |
Shares Outstanding (Diluted) | 203 | 155 | 59 | 40 | 39 | 22 |
Shares Change (YoY) | 105.12% | 160.95% | 49.90% | 0.40% | 75.46% | 35.68% |
EPS (Basic) | -0.01 | -0.01 | -0.13 | -0.27 | -0.43 | -4.66 |
EPS (Diluted) | -0.01 | -0.01 | -0.13 | -0.27 | -0.43 | -4.66 |
Free Cash Flow | -2.74 | -3.53 | -2.77 | -8.16 | -14.23 | -22.92 |
Free Cash Flow Per Share | -0.01 | -0.02 | -0.05 | -0.21 | -0.36 | -1.02 |
Gross Margin | 35.77% | 35.82% | 39.50% | 42.31% | 22.68% | 44.41% |
Operating Margin | -35.16% | -33.78% | -73.09% | -138.20% | -191.54% | -167.24% |
Profit Margin | -12.99% | -11.51% | -90.79% | -149.84% | -182.32% | -696.24% |
Free Cash Flow Margin | -17.26% | -23.60% | -33.50% | -115.62% | -152.40% | -152.67% |
EBITDA | -5.19 | -4.51 | -5.92 | -9.57 | -17.4 | -23.36 |
EBITDA Margin | -32.75% | -30.17% | -71.60% | -135.69% | -186.33% | -155.61% |
D&A For EBITDA | 0.38 | 0.54 | 0.12 | 0.18 | 0.49 | 1.75 |
EBIT | -5.57 | -5.05 | -6.04 | -9.75 | -17.89 | -25.1 |
EBIT Margin | -35.16% | -33.78% | -73.09% | -138.20% | -191.54% | -167.24% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.